New combo tackles tough breast cancer brain metastases

NCT ID NCT03483012

Completed Disease control Sponsor: Dana-Farber Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a combination of the immunotherapy drug atezolizumab and precise radiation (stereotactic radiosurgery) in 6 people with triple-negative breast cancer that had spread to the brain. The goal was to see if the combo could slow or stop the cancer from growing. The trial is now complete, but results are not yet widely available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Atezolizumab (Tecentriq) and stereotactic radiosurgery
What this could lead to: If successful, this combination could offer a new way to control triple-negative breast cancer that has spread to the brain, potentially improving survival.
What could go wrong: This is a very small, early-phase study (only 6 participants), so results may not apply to larger groups. The treatment may not work better than standard care and could cause side effects from both the drug and radiation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.